Concepts (60)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Porphyria Cutanea Tarda | 1 | 2020 | 15 | 0.710 |
Why?
|
| Hepatitis C | 1 | 2020 | 42 | 0.700 |
Why?
|
| Heme | 2 | 2019 | 61 | 0.690 |
Why?
|
| Porphobilinogen Synthase | 1 | 2019 | 10 | 0.660 |
Why?
|
| Porphyrias, Hepatic | 1 | 2019 | 12 | 0.660 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2017 | 60 | 0.590 |
Why?
|
| Liver Transplantation | 1 | 2017 | 179 | 0.560 |
Why?
|
| Liver Neoplasms | 1 | 2017 | 155 | 0.540 |
Why?
|
| Patient Selection | 1 | 2017 | 276 | 0.530 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 367 | 0.490 |
Why?
|
| Hepacivirus | 1 | 2020 | 39 | 0.180 |
Why?
|
| Mutation | 2 | 2019 | 489 | 0.170 |
Why?
|
| Coproporphyria, Hereditary | 1 | 2019 | 4 | 0.170 |
Why?
|
| Porphobilinogen | 1 | 2019 | 9 | 0.170 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2019 | 54 | 0.160 |
Why?
|
| Neuralgia | 1 | 2019 | 48 | 0.160 |
Why?
|
| Oxygen | 1 | 2019 | 142 | 0.160 |
Why?
|
| Ceruloplasmin | 1 | 2018 | 5 | 0.160 |
Why?
|
| Genes | 1 | 2018 | 15 | 0.150 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2017 | 9 | 0.150 |
Why?
|
| Energy Metabolism | 1 | 2019 | 147 | 0.150 |
Why?
|
| Tumor Burden | 1 | 2017 | 58 | 0.150 |
Why?
|
| Mitochondria | 1 | 2019 | 187 | 0.150 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2018 | 51 | 0.150 |
Why?
|
| Lymphatic Metastasis | 1 | 2017 | 166 | 0.150 |
Why?
|
| Hepatitis C, Chronic | 1 | 2017 | 77 | 0.150 |
Why?
|
| Anxiety | 1 | 2019 | 191 | 0.150 |
Why?
|
| Paracentesis | 1 | 2017 | 4 | 0.150 |
Why?
|
| Radiopharmaceuticals | 1 | 2017 | 93 | 0.140 |
Why?
|
| Catheter Ablation | 1 | 2017 | 67 | 0.140 |
Why?
|
| Ascites | 1 | 2017 | 16 | 0.140 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 190 | 0.140 |
Why?
|
| Liver Cirrhosis | 1 | 2017 | 81 | 0.140 |
Why?
|
| Humans | 7 | 2020 | 32005 | 0.140 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 447 | 0.140 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 608 | 0.100 |
Why?
|
| Coronary Artery Disease | 1 | 2010 | 401 | 0.070 |
Why?
|
| Myocardial Infarction | 1 | 2010 | 475 | 0.070 |
Why?
|
| Middle Aged | 4 | 2019 | 11817 | 0.050 |
Why?
|
| Electron Transport | 1 | 2019 | 16 | 0.040 |
Why?
|
| Adenosine Triphosphate | 1 | 2019 | 53 | 0.040 |
Why?
|
| Porphyria, Acute Intermittent | 1 | 2019 | 16 | 0.040 |
Why?
|
| Blood Platelets | 1 | 2019 | 39 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2019 | 56 | 0.040 |
Why?
|
| Male | 4 | 2019 | 19165 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2019 | 3990 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2019 | 545 | 0.040 |
Why?
|
| Virginia | 1 | 2017 | 63 | 0.040 |
Why?
|
| Hospitals, University | 1 | 2017 | 31 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2017 | 203 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2017 | 108 | 0.030 |
Why?
|
| Infant | 1 | 2019 | 1061 | 0.030 |
Why?
|
| Female | 3 | 2019 | 19959 | 0.030 |
Why?
|
| Adult | 2 | 2019 | 9345 | 0.030 |
Why?
|
| Aged | 2 | 2019 | 10301 | 0.030 |
Why?
|
| Physical Exertion | 1 | 2010 | 13 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2017 | 3306 | 0.020 |
Why?
|
| Stents | 1 | 2010 | 177 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2010 | 605 | 0.020 |
Why?
|
| Risk Factors | 1 | 2010 | 3876 | 0.010 |
Why?
|